Bionor provides an update on scientific collaborations
(Oslo, Norway, 13 June 2016) Bionor Pharma ASA (Bionor) (OSE:BIONOR), today provides an update on scientific collaborations in relation to the company’s HIV immunotherapy pipeline. On 31 May 2016, the Board of Directors announced a clinical strategy with continued focus on HIV immunotherapy and functional cure, which are complex scientific areas, and best pursued through …